Tevogen Bio Holdings Inc. (TVGNW) Análise de ações

Visão geral da empresa

A clinical-stage specialty immunotherapy company, Tevogen Bio Holdings Inc., focuses on the development of off-the-shelf, precision T cell therapies designed to treat infectious diseases, cancers, and various other disorders. The firm operates within the biotechnology and healthcare sectors, specifically targeting the clinical development pipeline for novel immunotherapies such as TVGN 489, which has completed Phase 1 clinical trials for the treatment of ambulatory conditions. According to the available financial data, the company employs 18 individuals, indicating a small-scale operational structure typical of early-stage clinical biotechnology firms. The reported market capitalization and annual revenue are not disclosed in the provided facts, which suggests that the company is likely in a pre-revenue or pre-commercialization phase where valuation is driven primarily by pipeline assets rather than current financial performance metrics. This lack of traditional market cap and revenue data highlights that the company's position is currently defined by its research and development progress rather than established market share or profitability.

Saúde financeira

The company reported a net income of $-26,825,432 over the trailing twelve months, while EBITDA stands at $-25,949,942, reflecting significant operational losses inherent to the clinical development stage. The substantial gap between the reported revenue, which is not listed in the available facts, and the negative net income reveals a cost structure dominated by research and development expenditures rather than cost of goods sold, a common characteristic for clinical-stage entities. Free cash flow for the period was $-1,774,858, indicating that the company is consuming cash reserves to fund its operations and clinical trials, thereby limiting its immediate financial flexibility without external capital raises. Analysis of the three primary margins shows that the gross margin is 0.0%, the operating margin is 0.0%, and the profit margin is 0.0%, figures that indicate the company has not yet achieved commercial revenue or is operating at a loss that precludes the calculation of positive margins. The balance sheet shows a cash balance of $552,372 against total debt of $7.50M, illustrating a leveraged position where liabilities significantly exceed liquid assets. The debt-to-equity ratio is not available in the provided data, but the disparity between cash and debt suggests a reliance on equity financing to service obligations. The current ratio is reported at 0.22, a figure that indicates severe short-term liquidity constraints, as current assets are less than 22% of current liabilities, raising concerns about the ability to meet immediate financial obligations. Return on Equity is not available, but the Return on Assets is calculated at -416.5%, a metric that reveals that management's utilization of assets has resulted in substantial losses relative to the asset base.

Avaliação de valorização

The trailing P/E ratio and forward P/E ratio are both not available, as the company has not generated positive earnings required to calculate these standard valuation metrics, implying that the market is not pricing the stock based on current or expected earnings per share. The price-to-book ratio is reported at -0.01, a negative figure that indicates the market capitalization is below the company's book value, which can occur when assets are recorded at historical costs while liabilities exceed equity. The price-to-sales ratio and EV/EBITDA are also not available, suggesting that alternative valuation methods are not applicable or are considered unreliable given the absence of positive revenue and earnings data. The stock has traded between a 52-week high of $0.03 and a 52-week low of $0.03, meaning the current price sits within a narrow range with zero percentage deviation from the high or low over the past year. The beta value is recorded at -0.30, a negative coefficient that suggests the stock price moves inversely to the broader market or exhibits volatility patterns distinct from typical equities, likely due to the speculative nature of clinical-stage biotechnology assets.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are not available in the provided facts, preventing a direct comparison of whether earnings are growing faster or slower than revenue. Since the company does not pay a dividend, the dividend yield and payout ratio are not available, indicating that the firm reinvests any available resources or raises capital to fund its research pipeline rather than distributing income to shareholders. This lack of dividend distribution is consistent with the growth strategy of clinical-stage companies that prioritize capital allocation toward asset development over shareholder payouts. The overall growth and income profile is characterized by a complete absence of historical financial growth metrics and dividend income, reflecting a capital-intensive business model focused entirely on advancing clinical trials and achieving product commercialization in the future.